Trial Profile

A Phase Ib Open-labeled, Multi-center, Dose-exploring Trial of SHR-1210 (Anti-PD-1 Antibody) in Combination With Apatinib and Fluzoparib in Subjects With Recurrent and Metastatic Triple Negative Breast Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camrelizumab (Primary) ; Fuzuloparib (Primary) ; Rivoceranib (Primary)
Indications Advanced breast cancer
Focus Adverse reactions
Sponsors Jiangsu Hengrui Medicine Co.

09 Aug 2022 Status changed from recruiting to completed.
17 Mar 2020 Planned End Date changed from 20 Dec 2020 to 20 Apr 2021.
17 Mar 2020 Planned primary completion date changed from 20 Dec 2019 to 20 Apr 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com